ישראל - עברית - Ministry of Health

קארין גל בעמ / נשיונל מוד בעמ - רעישה לע הנגה

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות פילם - ethinylestradiol 0.015 mg; gestodene 0.06 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליה - gestodene 0.075 mg; ethinylestradiol 0.030 mg - ethinylestradiol - ethinylestradiol - contraception.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

ישראל - עברית - Ministry of Health

merck serono ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 88 mcg/ml - interferon beta-1a

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.